Quick Answer
Aardvark Therapeutics, Inc. reported Diluted EPS of $2.93 per share (loss) for fiscal year 2025.
Aardvark Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.93 | +43.1% |
| 2024 | -$5.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.75 | +28.6% | -13.6% |
| June 30, 2025 | -$0.66 | +51.8% | +7.0% |
| March 31, 2025 | -$0.71 | -29.1% | +32.4% |
| September 30, 2024 | -$1.05 | — | +23.4% |
| June 30, 2024 | -$1.37 | — | -149.1% |
| March 31, 2024 | -$0.55 | — | — |
- Aardvark Therapeutics, Inc. showed an increase of +43.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Aardvark Therapeutics, Inc.’s diluted eps has grown by 43.1% (from $5.15 per share (loss) to $2.93 per share (loss)).
- The most recent figure is from Aardvark Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: